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almost always to loss of autonomous walking and forces the 
patients to use the wheelchair. Lung function becomes increas-
ingly compromised with the duration of the illness and assisted 
ventilation is required by non-invasive methods or by tracheos-
tomy. Dependence on a wheelchair usually starts a decade after 
the diagnosis while that on assisted ventilation may start earlier. 
Respiratory failure is almost always the cause of death in these 
patients. Today it seems possible to stop this tragic sequence of 
events by ERT, but for this purpose it is necessary to diagnose 
the disease at its early stages.
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The  heart  is  part  of  the  clinical  phenotype  of  Glyco-
gen storage disease type II (GDS II; Pompe disease; or acid 
maltase deficiency) since its original description. In 1932, Jo-
hannes Pompe, a Dutch pathologist, described the case of a 
7-month old infant who died suddenly for a severe idiopathic 
hypertrophy of the heart (1). Although other cases of massive 
hypertrophy of the heart have previously been described, Dr. 
Pompe first demonstrated that not only the heart was involved, 
but also other organs showed a vacuolar storage of glycogen 
(“cardiomegalia glycogenica”) (1). From a cardiologist’s point 
of view, Pompe disease is one of the leading cause of familial 
(idiopathic) hypertrophic cardiomyopathy in neonatal and pae-
diatric age (2). GSD II is broadly divided into two onset forms 
based on the age symptoms occur. 
Infantile onset (“Classic” Form)
In the classic infantile form (Pompe disease), cardiomy-
opathy and conduction disorders, along with muscular hypoto-
nia (“floppy baby”), macroglossia, and organomegalia, are the 
cardinal features.
Cardiomyopathy  is  generally  of  the  hypertrophic  type, 
demonstrating a severe thickening of the septum (“asymmetric” 
hypertrophy), or frequently of both the septum and free walls of 
the left and right heart (“concentric” hypertrophy). When the sep-
tal hypertrophy is very pronounced, a left outflow tract obstruc-
tion (favoured by a systolic anterior motion of the anterior mitral 
leaflet) may be present to worsen the disease (about 30% of the 
cases). Both diastolic and systolic dysfunction can be observed. 
Levine JC et al. showed a rapid regression of left ventricular 
hypertrophy in response to enzyme replacement therapy (ERT) 
in most of the patients, and systolic ventricular function was pre-
served despite rapid changes in ventricular mass and size (3). 
Glycogen  storage  involves  not  only  cardiac  myocytes, 
but also the special cells of the conduction system (particu-
larly,  the A-V  node  and  the  His-bundle  cells),  representing 
the hystological background of classical electrocardiographic 
abnormalities in Pompe disease: pre-excitation patterns (short 
PR, delta waves), atrio-ventricular blocks and bundle branch 
abnormalities. The  pathogenesis  of  ventricular  pre-excitation 
(Wolf Parkinson White syndrome, WPW, when symptomatic) 
is unknown, though is clear that the pattern does not reflect the 
presence of an accessory pathway (as in the classic WPW) (4). 
The suggested hypothesis are: a) a “direct insulating effect” of 
the glycogen on the conduction system; b) an “indirect insulat-
ing effect” of the glycogen on the conduction system, by the 
anatomic interruption of the annulus fibrosus (which acts as an 
“electric insulate” between the atria and the ventricles (4). 
Differential diagnosis
A metabolic or mitochondrial cardiomyopathy may mimic 
the presentation of GDSII cardiomyopathy (5). The presence of 
encephalomyopathy, metabolic acidosis (with or without hy-
poglycemia), the increase of lactate and lactate/piruvate ratio 
(normal: < 15:1; abnormal: 25:1) may suggest a mitochondrial 
cardiomyopathy. Hypoglycemia, with or without variation of 
plasma ketones, insulin, free fatty acids or carnitine may repre-
sent an hallmark of metabolic cardiomyopathies (i.e. beta oxi-
dation deficits). 
Infantile onset (“Non Classic” Form)
Compared to the classic form, the onset of the “non classic 
form” of Pompe disease is generally after the first year of age, 
with a less severe picture, including muscle weakness, cardio-
myopathy, and sometimes macroglossia and organomegalia. 
Conduction  abnormalities  and  ECG  signs  of  ventricular 
hypertrophy are generally part of the disease spectrum. Echocar-
diographic appearance of cardiac hypertrophy is generally less 
severe and progressive, lacking the left ventricular obstruction 
and the systolic dysfunction that significantly worsen the classic 
phenotype. However, the clinical presentation may be extremely 
various, as demonstrated by Suzuki et al. (6), which reported on 
a male who developed cardiomyopathy at 12 years of age and 
died of heart failure at age 15 years without any clinical and/or 
histological sign of skeletal myopathy. 
Differential diagnosis
On the cardiology point of view, the differential diagnosis is 
with overlapping phenotypes, including syndromic, mitochondri-
al or metabolic cardiomyopathies (5). Ventricular pre-excitation 
on the ECG and the presence of idiopathic left ventricular hyper-
trophy in children are common feature of storage diseases (AMP-
kinase  disease,  Danon  disease),  and  mitochondrial  disorders 
(MELAS, MERFF). Particularly, Danon disease is an X-linked 
glycogen storage disorder due to the absence of the LAMP-2, lys-
osome-associated membrane protein 2 (evidenced by Immuno-203
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histochemistry or by genetic sequencing). Compared with Pompe 
disease, cognitive impairment and retinitis pigmentosa may be 
distinctive features of the diseases. 
Adult Onset
Adult-onset acid maltase deficiency may simulate limb-gir-
dle dystrophy and the heart may represent a rare finding. Nev-
ertheless, the cardiac phenotype of adults with GDSII is poorly 
characterized, so far. 
Descriptions of heart abnormalities in adults with Pompe 
disease are sparse. Recently, a relatively large cohort of adults 
(87 patients, median age 44 years old, 51% males) with Pompe 
disease have been evaluated (7). A short PR interval was present 
in 10%, 7% showed a decreased left ventricular systolic func-
tion, and 5% had elevated left ventricular mass on echocardio-
gram. No change in cardiovascular status associated with en-
zyme replacement therapy (ERT) was observed. 
Severe vacuolization of vascular smooth muscle with ac-
cumulation of glycogen, particularly involving large and small 
cerebral  arteries  with  aneurysm  formation,  have  previously 
been reported (8, 9). Gungor D et al. (10) described survival 
of 268 patients with Pompe diseases, collected in a prospec-
tive international observational study conducted between 2002 
and 2009. Out of 34 deaths reported, the cause of death was 
recognized in 9 patients, including 1 patient who died for aortic 
dissection. The evidence of smooth muscle involvement seem 
to be confirmed by the finding of an increased aortic stiffness in 
adults with Pompe disease (11), which may be due to glycogen 
storage in the vessel wall, causing reduced vascular elasticity. 
These findings deserve future investigations. 
SUMMARY CLINICAL SYNOPSIS
Principal investigations:
•   ECG: short PR (WPW syndrome), signs of left ven-
tricular hypertrophy with repolarization abnormalities, 
Atrioventricular and/or intraventricular conduction de-
lays.
•   Echo:  left  ventricular  hypertrophy  (or,  biventricular 
hypertrophy), with or without: a) left ventricular out-
flow tract obstruction (about 30%); b) systolic dysfunc-
tion; c) diastolic dysfunction (generally, present).
Other investigations:
•   24 hours ECG Holter: intermittent WPW and/or con-
duction delays.
•   Functional capacity study: by six minute walking test 
and/or cardiopulmonary exercise test.
•   Cardiac  Magnetic  Resonance  Imaging  (CMRI),  with 
late gadolinueum analysis: to study cardiac morphology 
and function, and to determinate a non invasive, “texture 
characterization” of the cardiac muscle.
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Pompe disease is a single disease continuum that includes 
variable neuromuscular symptoms and rates of progression. 
However, specific clinical features, such as an early onset of 
respiratory problems preceding limb muscular weakness, dis-
tinguish Pompe disease from other neuromuscular diseases in 
which respiratory insufficiency occurs after loss of ambula-
tion. 
The  management  of  Pompe  disease  also  differs  from 
other neuromuscular diseases in that specific treatment is now 
available, making early recognition of the disease a priority. 
Late-onset form of Pompe disease, that may occur at any age 
after the first year of life, is characterized by slow and progres-
sive loss of function of skeletal muscles. Respiratory failure 
is the major cause of morbidity and mortality. The evaluation 
and monitoring of parameters such as FVC, MIP, MEP, blood 
gases, together with the clinical examination can delineate the 
profile and the decline in lung function, in order to provide 
early and effective therapeutic intervention. In patients with 
restrictive chest wall disease, the indication in VMD should be 
in the presence of symptoms such as fatigue, dyspnea, morn-
ing headaches, disturbed sleep, daytime hypersomnia associ-